Payment overview · 2025
General Payments
$844.26
39 reported records · 19 companies
Healthcare provider profile · identity verified
David E Nagata, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PHOENIX, AZ · NPI 1750371324
Verified facts
What the public records show
CMS Open Payments records show David E Nagata, MD received $844.26 in general payments during 2025 across 39 reported records.
Sumitomo Pharma America, Inc. accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $160.80 | 19.1% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $103.86 | 12.3% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $67.12 | 8.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $59.58 | 7.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $57.97 | 6.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.31 | 6.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.13 | 5.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.30 | 5.4% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $32.77 | 3.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.07 | 3.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.27 | 3.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.32 | 2.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.69 | 2.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.67 | 2.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.44 | 2.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.72 | 2.5% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $20.26 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.09 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.89 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $844.26 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $160.80 | 6 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $84.44 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $67.12 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $59.58 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $57.97 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.13 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $47.93 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.84 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $32.77 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $28.44 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 281 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 200 | 71 |
| Losartan Potassium | Losartan Potassium | 187 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 136 | 47 |
| Lisinopril | Lisinopril | 127 | 41 |
| Metformin Hcl | Metformin Hcl | 107 | 33 |
| Gabapentin | Gabapentin | 100 | 45 |
| Omeprazole | Omeprazole | 88 | 32 |
| Furosemide | Furosemide | 87 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 25 |
| Ezetimibe | Ezetimibe | 66 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 24 |
| Eliquis | Apixaban | 65 | 18 |
| Simvastatin | Simvastatin | 62 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 22 |
| Potassium Chloride | Potassium Chloride | 59 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 45 |
| Trazodone Hcl | Trazodone Hcl | 50 | 18 |
| Azithromycin | Azithromycin | 49 | 47 |
| Allopurinol | Allopurinol | 48 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 16 |
| Synthroid | Levothyroxine Sodium | 47 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 39 |
| Ozempic | Semaglutide | 41 | suppressed |
| Nifedipine Er | Nifedipine | 40 | 11 |
| Metformin Hcl Er | Metformin Hcl | 38 | 14 |
| Alendronate Sodium | Alendronate Sodium | 36 | 13 |
| Carvedilol | Carvedilol | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 15 |
| Levofloxacin | Levofloxacin | 32 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 14 |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 22 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 12 |
| Methylprednisolone | Methylprednisolone | 27 | 27 |
| Mirtazapine | Mirtazapine | 27 | 15 |
| Jardiance | Empagliflozin | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Erythromycin | Erythromycin Base | 18 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lactulose | Lactulose | 17 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Prednisone | Prednisone | 17 | 17 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | 12 |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $844.26 · 39 records | Sumitomo Pharma America, Inc. | ABRYSVO, AIRSUPRA, AVEIR, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, EVENITY, GEMTESA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, INSPIRE, JARDIANCE, JOT DX, KISUNLA, KYPHON EXPRESS II KYPHOPAK TRAY, Korlym, PREVNAR 20, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, VOQUEZNA, Veozah, WATCHMAN FLX, XIFAXAN, ZENPEP | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error